BR112014029095A2 - célula, linhagem celular derivada de célula, polinucleotídeo isolado, método de preparar uma proteína de múltiplas subunidades, proteína de múltiplas subunidades, e, célula de mamífero ex vivo - Google Patents

célula, linhagem celular derivada de célula, polinucleotídeo isolado, método de preparar uma proteína de múltiplas subunidades, proteína de múltiplas subunidades, e, célula de mamífero ex vivo

Info

Publication number
BR112014029095A2
BR112014029095A2 BR112014029095A BR112014029095A BR112014029095A2 BR 112014029095 A2 BR112014029095 A2 BR 112014029095A2 BR 112014029095 A BR112014029095 A BR 112014029095A BR 112014029095 A BR112014029095 A BR 112014029095A BR 112014029095 A2 BR112014029095 A2 BR 112014029095A2
Authority
BR
Brazil
Prior art keywords
cell
subunit protein
multiple subunit
preparing
edem2
Prior art date
Application number
BR112014029095A
Other languages
English (en)
Inventor
Burakov Darya
Deshpande Dipali
Chen Gang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014029095A2 publication Critical patent/BR112014029095A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

1 / 1 resumo “cã‰lula, linhagem celular derivada de cã‰lula, polinucleotãdeo isolado, mã‰todo de preparar uma proteãna de mãšltiplas subunidades, proteãna de mãšltiplas subunidades, e, cã‰lula de mamãfero ex vivo” a presente invenã§ã£o refere-se ã  descoberta da expressã£o ectã³pica de edem2 em uma cã©lula de produã§ã£o para melhora o rendimento de uma proteã­na de mãºltiplas subunidades usada. assim, a presente invenã§ã£o fornece linhagens celulares de produã§ã£o, tal como a cã©lula de produã§ã£o canã´nica biofarmacãªutica de mamã­fero – a cã©lula cho, contendo polinucleotã­deos recombinantes que codificam edem2. ㉠tambã©m revelada uma cã©lula de produã§ã£o contendo tanto um polinucleotã­deo que codifica edem2 quanto um polinucleotã­deo que codifica xbp1. melhores titulaã§ãµes de anticorpos produzidos por estas linhagens celulares sã£o reveladas, bem como as melhores densidades celulares atingidas por estas cã©lulas em cultura.
BR112014029095A 2012-05-29 2013-05-29 célula, linhagem celular derivada de célula, polinucleotídeo isolado, método de preparar uma proteína de múltiplas subunidades, proteína de múltiplas subunidades, e, célula de mamífero ex vivo BR112014029095A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers
PCT/US2013/043116 WO2013181253A1 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (1)

Publication Number Publication Date
BR112014029095A2 true BR112014029095A2 (pt) 2017-07-18

Family

ID=49670701

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029095A BR112014029095A2 (pt) 2012-05-29 2013-05-29 célula, linhagem celular derivada de célula, polinucleotídeo isolado, método de preparar uma proteína de múltiplas subunidades, proteína de múltiplas subunidades, e, célula de mamífero ex vivo

Country Status (21)

Country Link
US (9) US9079954B2 (pt)
EP (3) EP3564262A1 (pt)
JP (5) JP6298455B2 (pt)
KR (4) KR102528950B1 (pt)
CN (2) CN104350068B (pt)
AU (4) AU2013267525B2 (pt)
BR (1) BR112014029095A2 (pt)
CA (1) CA2873131A1 (pt)
DK (1) DK2875047T3 (pt)
EA (2) EA028790B1 (pt)
ES (1) ES2940900T3 (pt)
FI (1) FI2875047T3 (pt)
HK (1) HK1205137A1 (pt)
HU (1) HUE061479T2 (pt)
IL (3) IL235573B (pt)
MX (1) MX360359B (pt)
PL (1) PL2875047T3 (pt)
SG (2) SG11201407652RA (pt)
TW (2) TW201823460A (pt)
WO (1) WO2013181253A1 (pt)
ZA (1) ZA201408289B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EA201892137A1 (ru) 2016-04-20 2019-03-29 Регенерон Фармасьютикалз, Инк. Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
SG10202010155YA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3541365A1 (en) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2003101189A1 (en) 2002-05-29 2003-12-11 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2496897C (en) 2002-08-30 2012-01-31 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
NZ544335A (en) 2003-06-11 2009-01-31 Biogen Idec Inc Method to increase protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2561702C (en) * 2004-03-31 2018-05-15 Centocor, Inc. Methods for altering protein production rates
WO2006014678A2 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
JP2008511335A (ja) * 2004-09-02 2008-04-17 ワイス 蛋白を作製するための系および方法
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
DK2129685T3 (da) 2007-03-21 2014-02-10 Danisco Us Inc Overekspression af foldaser og chaperoner forbedrer proteinfremstilling
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
ES2646614T3 (es) * 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2209891A1 (en) 2007-11-13 2010-07-28 Boehringer Ingelheim Pharma GmbH & Co. KG Improving the secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
CA2726289A1 (en) 2008-05-28 2009-12-23 Bayer Healthcare Llc Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) * 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
PL2808393T3 (pl) 2009-06-02 2018-04-30 Regeneron Pharmaceuticals, Inc. Komórki z brakiem fukozylacji
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
CA2888803A1 (en) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Also Published As

Publication number Publication date
JP6298455B2 (ja) 2018-03-20
KR20200074273A (ko) 2020-06-24
US10351622B2 (en) 2019-07-16
KR20230065370A (ko) 2023-05-11
KR102528950B1 (ko) 2023-05-08
JP2018108094A (ja) 2018-07-12
JP2015518728A (ja) 2015-07-06
AU2013267525A1 (en) 2014-12-11
KR102126210B1 (ko) 2020-06-25
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
HUE061479T2 (hu) 2023-07-28
AU2018201094B2 (en) 2019-06-20
JP7037535B2 (ja) 2022-03-16
EA201492242A1 (ru) 2015-05-29
AU2021240303A1 (en) 2021-10-28
KR20220003165A (ko) 2022-01-07
CN104350068A (zh) 2015-02-11
MX2014014630A (es) 2015-02-12
CA2873131A1 (en) 2013-12-05
US20150299309A1 (en) 2015-10-22
US20150299310A1 (en) 2015-10-22
US10611831B2 (en) 2020-04-07
ES2940900T3 (es) 2023-05-12
KR102346867B1 (ko) 2022-01-04
AU2019203780A1 (en) 2019-06-20
US20150175688A1 (en) 2015-06-25
SG11201407652RA (en) 2014-12-30
JP2020022514A (ja) 2020-02-13
US20190270800A1 (en) 2019-09-05
US9228012B2 (en) 2016-01-05
EA201792213A1 (ru) 2018-01-31
US20150353634A1 (en) 2015-12-10
US9688751B2 (en) 2017-06-27
JP2022044609A (ja) 2022-03-17
FI2875047T3 (fi) 2023-03-30
EP2875047A1 (en) 2015-05-27
MX360359B (es) 2018-10-30
EA028790B1 (ru) 2017-12-29
AU2019203780B2 (en) 2021-07-01
US9079954B2 (en) 2015-07-14
IL265867A (en) 2019-06-30
US9193786B2 (en) 2015-11-24
IL235573B (en) 2019-09-26
KR20150015492A (ko) 2015-02-10
TW201402815A (zh) 2014-01-16
EP4219546A2 (en) 2023-08-02
CN104350068B (zh) 2019-12-03
US20170291938A1 (en) 2017-10-12
ZA201408289B (en) 2016-09-28
IL235573A0 (en) 2015-01-29
KR102663134B1 (ko) 2024-05-03
AU2013267525B2 (en) 2017-11-16
EP4219546A3 (en) 2023-08-23
JP2023153268A (ja) 2023-10-17
US20160304598A1 (en) 2016-10-20
JP7382383B2 (ja) 2023-11-16
CN110835624A (zh) 2020-02-25
EP3564262A1 (en) 2019-11-06
US10227401B2 (en) 2019-03-12
AU2018201094A1 (en) 2018-03-15
USRE48651E1 (en) 2021-07-20
HK1205137A1 (en) 2015-12-11
US20130323788A1 (en) 2013-12-05
SG10201606654XA (en) 2016-10-28
EP2875047B1 (en) 2023-01-25
US9382315B2 (en) 2016-07-05
IL279922A (en) 2021-03-01
DK2875047T3 (da) 2023-03-27
JP6622334B2 (ja) 2019-12-18
TW201823460A (zh) 2018-07-01
WO2013181253A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
BR112014029095A2 (pt) célula, linhagem celular derivada de célula, polinucleotídeo isolado, método de preparar uma proteína de múltiplas subunidades, proteína de múltiplas subunidades, e, célula de mamífero ex vivo
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
IN2014CN04586A (pt)
MY182355A (en) Hmo synthesis
BRPI1007214A2 (pt) adaptador para sequenciar ácidos nucleicos, par de adaptadores, kit, construto de ácido nucleico, e, métodos para preparar um adaptador, um construto de ácido nucleico, e um construto de dequência, e para sequenciar ácido nucleico de fita dupla.
MX337985B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
BR112015011534A2 (pt) polipeptídeo recombinante de myceliophthera thermophilus, ácido nucleico isolado, vetor recombinante, célula hospedeira recombinante, métodos para produzir um polipeptídeo, para degradar uma biomassa celulósica, para aumentar a produção de proteínas ativas a partir de uma célula hospedeira, e, composição
BR112012027282A2 (pt) meio de cultura de células aperfeiçoado
AR080942A1 (es) Produccion de proteinas heteromultimericas
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
BR112016002067A2 (pt) Variantes de enzimas
BR112018002214A2 (pt) ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho?
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
EA201270286A1 (ru) Варианты глюкоамилазы
MX2012006096A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
MX351565B (es) Colageno 7 y metodos relacionados.
EA201100225A1 (ru) Новые регуляторные элементы
CL2008003596A1 (es) Fitasa enzimaticamente susceptible, polinucleotido que la codifica, casete de expresion, vector y celula huesped que comprenden dicho acido nucleico; metodo de preparacion de la fitasa, y composiciones que la comprenden.
BR112014029252A2 (pt) método para a construção de uma célula hospedeira fúngica recombinante, construto de polinucleotídeo, célula hospedeira fúngica recombinante, e, método de produção de um polipeptídeo de interesse
EP2576626A4 (en) FUNCTIONAL AND STABLE CLASS I CELLOBIOHYDROLASTIC ENZYMES
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]